Effect of sodium ozagrel on the activity of rat CYP2D6

被引:5
|
作者
Wu, Hong
Yu, Weijiang
Huang, Lijun
Wang, Jing
Tang, Xiaobo
Yang, Wei
Liu, Yan
Yu, Huiyan
Zhu, Daling
机构
[1] Harbin Med Univ, Coll Pharm, Harbin 150081, Heilongjiang, Peoples R China
[2] Biopharmaceut Key Lab Heilongjiang Prov, Harbin 150081, Peoples R China
[3] Mudanjiang Med Coll, Mudanjiang 157011, Peoples R China
关键词
ozagrel-1; CYP2D6; microsorne; HPLC; dextromethorphan;
D O I
10.1016/j.ejphar.2007.06.055
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the study was to investigate the influence of sodium ozagrel on CYP2D6 (cytochromeP450 2D6) activity. The studies were performed with rat urine and liver microsomes and chemical inhibitors. The metabolism of dextromethorphan (dextrophan/dextromethorphan, dextrophan is a metabolite of dextromethorphan) and phenacetin (paracetamol/phenacetin, paracetamol is a metabolites of phenacetin) was used as probe to measure CYP2D6 and CYP1A2 (cytochromeP450 1A2) activity, respectively, determined by high-performance liquid chromatography (HPLC). The results showed that the metabolism of dextrophan/dextromethorphan in the sodium ozagrel-treated group (37 mg/kg) was higher than that of the control (P < 0.05/6) in both in vivo and in vitro studies (r=0.9811). The rate of dextromethorphan metabolism was inhibited by sodium ozagrel and cimetidine in rat liver microsomes prepared from sodium ozagrel-treated rats and control rats group (sodium ozagrel IC50=26.5 mu M, cimetidine IC50=86.3 mu M in sodium ozagrel-treated group; sodium ozagrel IC50=13.9 mu M, cimetidine IC50=24.8 mu M in control group). The inhibitory effect of sodium ozagrel on CYP2D6 activity was noncompetitive with dextromethorphan with a K-i of 324.94 mu M. Kinetic parameters of the reactions were established by using Lineweaver-Burk with K-m=0.67 mM and V-max = 2.13 pm/min/mg protein for the sodium ozagrel-treated group and K-m=0.29 mM, and V-max =0.91 pm/min/mg protein for the control group, respectively. The expression of CYP2D6 protein in the treated group was higher than that of the control group, as determined by Western blotting. The activity and expression of CYP1A2 did not show obvious differences in the control group and sodium ozagrel treated group. In conclusion, sodium ozagrel metabolism in rats is mediated primarily through CYP2D6, and sodium ozagrel can induce CYP2D6 activity. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:55 / 59
页数:5
相关论文
共 50 条
  • [41] In vivo indices of enzyme activity:: the effect of renal impairment on the assessment of CYP2D6 activity
    Rostami-Hodjegan, A
    Funck-Brentano, C
    Kroemer, HK
    Tucker, GT
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (05) : 577 - 578
  • [42] The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity
    Bojic, Mirza
    Kondza, Martin
    Rimac, Hrvoje
    Benkovic, Goran
    Males, Zeljan
    MOLECULES, 2019, 24 (17):
  • [43] Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3,*4, and*6), and the metabolic capacity of CYP2D6 in Northern Iranian Population (Mazandaran)
    Shiran, Mohammad R.
    Soteh, Mohammad B. Hashemi
    Merat, Fatemeh
    Sarzare, Fatemeh
    Salehifar, Ebrahim
    DRUG METABOLISM REVIEWS, 2010, 42 : 260 - 261
  • [44] Analysis of CYP2D6 expression in human lung: Implications for the association between CYP2D6 activity and susceptibility to lung cancer
    Kivisto, KT
    Griese, KU
    Stuven, T
    Fritz, P
    Friedel, G
    Kroemer, HK
    Zanger, UM
    PHARMACOGENETICS, 1997, 7 (04): : 295 - 302
  • [45] Human liver CYP2D6 genotype, full-length mRNA, and activity, assessed with a novel CYP2D6 substrate
    Bodor, M
    McConnachie, L
    Kowdley, K
    Levy, A
    Tun, B
    Thummel, K
    Phillips, B
    Bajpai, M
    Chi, V
    Esmay, JD
    Shen, DD
    Ho, RJY
    DRUG METABOLISM REVIEWS, 2004, 36 : 113 - 113
  • [46] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation:: a study of mutations CYP2D6*3 and CYP2D6*4
    Monek, O
    Paintaud, G
    Bechtel, Y
    Miguet, JP
    Mantion, G
    Bechtel, PR
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (01) : 47 - 52
  • [47] Impact of Pregnancy and Vitamin A Supplementation on CYP2D6 Activity
    Amaeze, Ogochukwu U.
    Czuba, Lindsay C.
    Yadav, Aprajita S.
    Fay, Emily E.
    LaFrance, Jeffrey
    Shum, Sara
    Moreni, Sue L.
    Mao, Jennie
    Huang, Weize
    Isoherranen, Nina
    Hebert, Mary F.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (03): : 363 - 372
  • [48] In vitro inhibition of CYP2D6 activity by fenfluramine.
    Marcucci, K
    Gotschall, R
    Kearns, GL
    Leeder, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 142 - 142
  • [49] Solanidine is a sensitive and specific biomarker for CYP2D6 activity
    Kiiski, Johanna I.
    Neuvonen, Mikko
    Hirvensalo, Paivi
    Kurkela, Mika
    Hamalainen, Kreetta
    Lehtonen, Marko
    Filppula, Anne M.
    Niemi, Mikko
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2023, 132 : 15 - 16
  • [50] Pinoline May be Used as a Probe for CYP2D6 Activity
    Jiang, Xi-Ling
    Shen, Hong-Wu
    Yu, Ai-Ming
    DRUG METABOLISM AND DISPOSITION, 2009, 37 (03) : 443 - 446